About OXGENE
OXGENE is a company based in Oxford (United Kingdom) founded in 2011 was acquired by WuXi AppTec in March 2021. OXGENE has raised $28.09 million across 13 funding rounds from investors including Gov.uk, WuXi AppTec and Canaccord Genuity Group. The company has 102 employees as of December 31, 2021. OXGENE operates in a competitive market with competitors including Inscripta, Poseida Therapeutics, Senti Biosciences, GenScript and ADARx Pharmaceuticals, among others.
- Headquarter Oxford, United Kingdom
- Employees 102 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Oxford Genetics Ltd
- Date of Incorporation 28 Apr, 2011
- Jurisdiction OXFORD, UNITED KINGDOM
-
Annual Revenue
$110.6 K (USD)-35as on Dec 31, 2023
-
Net Profit
-$43.65 K (USD)-257as on Dec 31, 2023
-
EBITDA
-$42.48 K (USD)-309as on Dec 31, 2023
-
Total Equity Funding
$28.09 M (USD)
in 13 rounds
-
Latest Funding Round
$1.02 M (USD), Series A
Jul 07, 2025
-
Investors
Gov.uk
& 4 more
-
Employee Count
102
as on Dec 31, 2021
-
Acquired by
WuXi AppTec
(Mar 02, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of OXGENE
Unlock access to complete
Unlock access to complete
Funding Insights of OXGENE
OXGENE has successfully raised a total of $28.09M across 13 strategic funding rounds. The most recent funding activity was a Series A round of $1.02 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OXGENE
OXGENE has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include Gov.uk, WuXi AppTec and Canaccord Genuity Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment management services are provided by Mercia to various clients.
|
Locked | Locked | Locked | |
|
Merger and acquisitions advisory firm
|
Locked | Locked | Locked | |
|
Diversified asset management services are offered globally by Invesco.
|
Locked | Locked | Locked |
Investor details for OXGENE
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OXGENE
Investment portfolio details for OXGENE
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OXGENE
Detailed financials for OXGENE
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oxgene Comparisons
Peer comparison for OXGENE
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OXGENE
OXGENE operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inscripta, Poseida Therapeutics, Senti Biosciences, GenScript and ADARx Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Speech recognition solutions are provided by Inscripta for healthcare professionals.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts
|
|
| Locked | Locked | Locked |
Genomic and theranostic services for oncology precision medicine are delivered.
|
Detailed competitors of OXGENE
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oxgene
Complete news archive for OXGENE
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OXGENE
OXGENE was founded in 2011.
OXGENE is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
OXGENE is a funded company, having raised a total of $28.09M across 13 funding rounds to date.
As of Dec 31, 2021, the latest employee count at OXGENE is 102.
Annual revenue of OXGENE is $110.6K as on Dec 31, 2023.
OXGENE was founded in 2011 in Oxford, United Kingdom, and operates in the biotechnology sector. A platform for mammalian cell engineering is offered, along with plasmid and DNA component products and SnapFast plasmid technology. DNA sequences are designed, protein expression is optimized, cell lines are developed, and viral delivery systems are improved. Bioinformatics and gene-editing technologies are integrated to support streamlined workflows for cell line production.
OXGENE's top competitors include CRISPR Therapeutics, Senti Biosciences and Poseida Therapeutics.
OXGENE has 5 investors. Key investors include Gov.uk, WuXi AppTec, Canaccord Genuity Group, Mercia, and Invesco.